{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:00:05Z","timestamp":1792501205089,"version":"4.5.0"},"reference-count":51,"publisher":"Bentham Science Publishers Ltd.","issue":"6","funder":[{"DOI":"10.13039\/501100004748","name":"Research Council of Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["961916"],"award-info":[{"award-number":["961916"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Galbanic acid (GBA) is a sesquiterpene coumarin with valuable pharmacological effects.\nAdult T-cell lymphoma (ATL) is an aggressive lymphoid malignancy with a low survival rate. Although arsenic trioxide\n(ATO) is a standard therapeutic agent for ATL treatment, the efficacy of chemotherapy is limited due to the chemoresistance\nof cells.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The present study was carried out to investigate whether GBA in combination with ATO would improve\ncytotoxicity against ATL cells.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>GBA was isolated from the roots of Ferula szowitsiana by column chromatography on silica gel. MT-2 cells\nwere treated with 20 \u03bcM GBA + 4 \u03bcM ATO, and viability was evaluated by alamarBlue assay. The cell cycle was\nanalyzed by PI staining, while the activity of P-glycoprotein (P-gp) was evaluated by mitoxantrone efflux assay. To\nunderstand the molecular mechanisms of GBA effects, the expression of NF-\u03baB (RelA), P53, CDK4, c-MYC, c-FLIPL,\nand c-FLIPS was evaluated using real-time PCR.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Combinatorial use of GBA + ATO significantly reduced the viability of MT-2 cells and induced cell cycle\narrest in the sub-G1 phase. GBA improved mitoxantrone accumulation in cells, indicating that this agent has inhibitory\neffects on the functionality of the P-gp efflux pump. Moreover, real-time PCR analysis revealed that GBA + ATO\nnegatively regulated the expression of P53, CDK4, c-FLIPL, and c-FLIPS.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Due to the interesting effects of GBA on the accumulation and toxicity of ATO, combinatorial use of\nthese agents could be considered a new therapeutic approach for ATL treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871520622666220722105802","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T10:58:06Z","timestamp":1658487486000},"page":"699-708","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Galbanic Acid Improves Accumulation and Toxicity of Arsenic Trioxide in MT-2\nCells"],"prefix":"10.2174","volume":"23","author":[{"given":"Fatemeh B.","family":"Rassouli","sequence":"first","affiliation":[{"name":"Novel Diagnostics and Therapeutics Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houshang","family":"Rafatpanah","sequence":"first","affiliation":[{"name":"Inflammation and Inflammatory Diseases Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Mahdifar","sequence":"additional","affiliation":[{"name":"Inflammation and Inflammatory Diseases Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Iranshahi","sequence":"additional","affiliation":[{"name":"Department of Pharmacognosy and Biotechnology, Biotechnology Research Center, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajad","family":"Goudarzi","sequence":"additional","affiliation":[{"name":"Cancer Molecular Pathology Research Center, Department of Hematology and Blood Bank, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzieh","family":"Golizadeh","sequence":"additional","affiliation":[{"name":"Inflammation and Inflammatory Diseases Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12325-018-0658-4","volume":"35","author":"Hermine O.","year":"2018","unstructured":"Hermine O.; Ramos J.C.; Tobinai K.; A review of new findings in adult T-celllLeukemia-lymphoma: A focus on current and emerging treatment strategies. Adv Ther 2018,35(2),135-152","journal-title":"Adv Ther"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"11685","DOI":"10.1073\/pnas.1920346117","volume":"117","author":"Nagasaka M.","year":"2020","unstructured":"Nagasaka M.; Yamagishi M.; Yagishita N.; Araya N.; Kobayashi S.; Makiyama J.; Kubokawa M.; Yamauchi J.; Hasegawa D.; Coler-Reilly A.L.G.; Tsutsumi S.; Uemura Y.; Arai A.; Takata A.; Inoue E.; Hasegawa Y.; Watanabe T.; Suzuki Y.; Uchimaru K.; Sato T.; Yamano Y.; Mortality and risk of progression to adult T cell leukemia\/lymphoma in HTLV-1-associated myelopathy\/tropical spastic paraparesis. Proc Natl Acad Sci USA 2020,117(21),11685-11691","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"26270","DOI":"10.1074\/jbc.M115.684746","volume":"290","author":"Cherian M.A.","year":"2015","unstructured":"Cherian M.A.; Baydoun H.H.; Al-Saleem J.; Shkriabai N.; Kvaratskhelia M.; Green P.; Ratner L.; Akt pathway activation by human T-cell leukemia virus type 1 Tax oncoprotein. J Biol Chem 2015,290(43),26270-26281","journal-title":"J Biol Chem"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"16288","DOI":"10.1016\/S0021-9258(18)41998-9","volume":"267","author":"Duyao M.P.","year":"1992","unstructured":"Duyao M.P.; Kessler D.J.; Spicer D.B.; Bartholomew C.; Cleveland J.L.; Siekevitz M.; Sonenshein G.E.; Transactivation of the c-myc promoter by human T cell leukemia virus type 1 tax is mediated by NF kappa B. J Biol Chem 1992,267(23),16288-16291","journal-title":"J Biol Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1182\/blood-2005-06-2567","volume":"107","author":"Krueger A.","year":"2006","unstructured":"Krueger A.; Fas S.C.; Giaisi M.; Bleumink M.; Merling A.; Stumpf C.; Baumann S.; Holtkotte D.; Bosch V.; Krammer P.H.; Li-Weber M.; HTLV-1 Tax protects against CD95-mediated apoptosis by induction of the cellular FLICE-inhibitory protein (c-FLIP). Blood 2006,107(10),3933-3939","journal-title":"Blood"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1111\/febs.14492","volume":"285","author":"Harhaj E.W.","year":"2018","unstructured":"Harhaj E.W.; Giam, C.Z. NF-&#x3BA;B signaling mechanisms in HTLV-1-induced adult T-cell leukemia\/lymphoma. FEBS J 2018,285(18),3324-3336","journal-title":"FEBS J"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/j.1460-2075.1996.tb00505.x","volume":"15","author":"Suzuki T.","year":"1996","unstructured":"Suzuki T.; Kitao S.; Matsushime H.; Yoshida M.; HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p16INK4A and counteracts its inhibitory activity towards CDK4. EMBO J 1996,15(7),1607-1614","journal-title":"EMBO J"},{"key":"ref=8","author":"Abeloff M.D.","year":"2008","unstructured":"Abeloff M.D.;  Abeloff\u2019s Clinical Oncology E-Book 2008","journal-title":"Abeloff\u2019s Clinical Oncology E-Book"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","volume":"15","author":"Ishitsuka K.","year":"2014","unstructured":"Ishitsuka K.; Tamura K.; Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol 2014,15(11),e517-e526","journal-title":"Lancet Oncol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1742-4690-10-91","volume":"10","author":"Kchour G.","year":"2013","unstructured":"Kchour G.; Rezaee R.; Farid R.; Ghantous A.; Rafatpanah H.; Tarhini M.; Kooshyar M.M.; El Hajj H.; Berry F.; Mortada M.; Nasser R.; Shirdel A.; Dassouki Z.; Ezzedine M.; Rahimi H.; Ghavamzadeh A.; de Th&#xE9; H.; Hermine O.; Mahmoudi M.; Bazarbachi A.; The combination of arsenic, interferon-alpha, and zidovudine restores an &#x201C;immunocompetent-like&#x201D; cytokine expression profile in patients with adult T-cell leukemia lymphoma. Retrovirology 2013,10(1),91","journal-title":"Retrovirology"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/leu.2011.245","volume":"26","author":"Lengfelder E.","year":"2012","unstructured":"Lengfelder E.; Hofmann W.K.; Nowak D.; Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia 2012,26(3),433-442","journal-title":"Leukemia"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1039\/c9mt00308h","volume":"12","author":"Wang Q.Q.","year":"2020","unstructured":"Wang Q.Q.; Jiang Y.; Naranmandura H.; Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases. Metallomics 2020,12(3),326-336","journal-title":"Metallomics"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1080\/10428190290021461","volume":"43","author":"Ishitsuka K.","year":"2002","unstructured":"Ishitsuka K.; Ikeda R.; Utsunomiya A.; Uozumi K.; Hanada S.; Suzuki S.; Takeuchi S.; Takatsuka Y.; Takeshita T.; Ohno N.; Arima T.; Arsenic trioxide induces apoptosis in HTLV-I infected T-cell lines and fresh adult T-cell leukemia cells through CD95 or tumor necrosis factor alpha receptor independent caspase activation. Leuk Lymphoma 2002,43(5),1107-1114","journal-title":"Leuk Lymphoma"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1182\/blood.V98.13.3762","volume":"98","author":"Mahieux R.","year":"2001","unstructured":"Mahieux R.; Pise-Masison C.; Gessain A.; Brady J.N.; Olivier R.; Perret E.; Misteli T.; Nicot C.; Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 2001,98(13),3762-3769","journal-title":"Blood"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1182\/blood.V93.1.278","volume":"93","author":"Bazarbachi A.","year":"1999","unstructured":"Bazarbachi A.; El-Sabban M.E.; Nasr R.; Quignon F.; Awaraji C.; Kersual J.; Dianoux L.; Zermati Y.; Haidar J.H.; Hermine O.; de Th&#xE9; H.; Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999,93(1),278-283","journal-title":"Blood"},{"key":"ref=16","first-page":"2849","volume":"96","author":"El-Sabban M.E.","year":"2000","unstructured":"El-Sabban M.E.; Nasr R.; Dbaibo G.; Hermine O.; Abboushi N.; Quignon F.; Ameisen J.C.; Bex F.; de Th&#xE9; H.; Bazarbachi A.; Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood 2000,96(8),2849-2855","journal-title":"Blood"},{"key":"ref=17","first-page":"296","volume":"8","author":"Iranshahi M.","year":"2018","unstructured":"Iranshahi M.; Rezaee R.; Najaf Najafi M.; Haghbin A.; Kasaian J.; Cytotoxic activity of the genus Ferula (Apiaceae) and its bioactive constituents. Avicenna J Phytomed 2018,8(4),296-312","journal-title":"Avicenna J Phytomed"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/S0031-9422(01)00324-7","volume":"58","author":"Abd El-Razek M.H.","year":"2001","unstructured":"Abd El-Razek M.H.; Ohta S.; Ahmed A.A.; Hirata T.; Sesquiterpene coumarins from the roots of Ferula assa-foetida. Phytochemistry 2001,58(8),1289-1295","journal-title":"Phytochemistry"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.phytochem.2006.11.002","volume":"68","author":"Iranshahi M.","year":"2007","unstructured":"Iranshahi M.; Arfa P.; Ramezani M.; Jaafari M.R.; Sadeghian H.; Bassarello C.; Piacente S.; Pizza C.; Sesquiterpene coumarins from Ferula szowitsiana and in vitro antileishmanial activity of 7-prenyloxycoumarins against promastigotes. Phytochemistry 2007,68(4),554-561","journal-title":"Phytochemistry"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1055\/s-2008-1034293","volume":"74","author":"Iranshahi M.","year":"2008","unstructured":"Iranshahi M.; Kalategi F.; Rezaee R.; Shahverdi A.R.; Ito C.; Furukawa H.; Tokuda H.; Itoigawa M.; Cancer chemopreventive activity of terpenoid coumarins from Ferula species. Planta Med 2008,74(2),147-150","journal-title":"Planta Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jep.2010.11.067","volume":"134","author":"Iranshahy M.","year":"2011","unstructured":"Iranshahy M.; Iranshahi M.; Traditional uses, phytochemistry and pharmacology of asafoetida (Ferula assa-foetida oleo-gum-resin)-A review. J Ethnopharmacol 2011,134(1),1-10","journal-title":"J Ethnopharmacol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3109\/13880209.2013.846916","volume":"52","author":"Kasaian J.","year":"2014","unstructured":"Kasaian J.; Iranshahy M.; Iranshahi M.; Synthesis, biosynthesis and biological activities of galbanic acid\u2013A review. Pharm Biol 2014,52(4),524-531","journal-title":"Pharm Biol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s11095-010-0311-7","volume":"28","author":"Kim K.H.","year":"2011","unstructured":"Kim K.H.; Lee H.J.; Jeong S.J.; Lee H.J.; Lee E.O.; Kim H.S.; Zhang Y.; Ryu S.Y.; Lee M.H.; L&#xFC; J.; Kim S.H.; Galbanic acid isolated from Ferula assafoetida exerts in vivo anti-tumor activity in association with anti-angiogenesis and anti-proliferation. Pharm Res 2011,28(3),597-609","journal-title":"Pharm Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2174\/1874467213666200512075507","volume":"14","author":"Shahcheraghi S.H.","year":"2021","unstructured":"Shahcheraghi S.H.; Lotfi M.; Soukhtanloo M.; Ghayour Mobarhan M.; Jaliani H.Z.; Sadeghnia H.R.; Ghorbani A.; Effects of galbanic acid on proliferation, migration, andaApoptosis of glioblastoma cells through the PI3K\/Akt\/MTOR signaling pathway. Curr Mol Pharmacol 2021,14(1),79-87","journal-title":"Curr Mol Pharmacol"},{"key":"ref=25","first-page":"1934578X211046068","volume":"16","author":"Hashemi R.","year":"2021","unstructured":"Hashemi R.; In vitro study of radiosensitivity effects of galbanic acid on ovarian tumor cells (OVCAR-3 Cell Line). Nat. Prod. Commun. 2021,16(10),1934578X211046068"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1055\/s-0030-1270987","volume":"77","author":"Hanafi-Bojd M.Y.","year":"2011","unstructured":"Hanafi-Bojd M.Y.; Iranshahi M.; Mosaffa F.; Tehrani S.O.; Kalalinia F.; Behravan J.; Farnesiferol A from Ferula persica and galbanic acid from Ferula szowitsiana inhibit P-glycoprotein-mediated rhodamine efflux in breast cancer cell lines. Planta Med 2011,77(14),1590-1593","journal-title":"Planta Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"6528","DOI":"10.1182\/blood-2009-03-211821","volume":"113","author":"Kchour G.","year":"2009","unstructured":"Kchour G.; Tarhini M.; Kooshyar M.M.; El Hajj H.; Wattel E.; Mahmoudi M.; Hatoum H.; Rahimi H.; Maleki M.; Rafatpanah H.; Rezaee S.A.; Yazdi M.T.; Shirdel A.; de Th&#xE9; H.; Hermine O.; Farid R.; Bazarbachi A.; Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia\/lymphoma (ATL). Blood 2009,113(26),6528-6532","journal-title":"Blood"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.fitote.2014.12.003","volume":"101","author":"Eskandani M.","year":"2015","unstructured":"Eskandani M.; Abdolalizadeh J.; Hamishehkar H.; Nazemiyeh H.; Barar J.; Galbanic acid inhibits HIF-1&#x3B1; expression via EGFR\/HIF-1&#x3B1; pathway in cancer cells. Fitoterapia 2015,101,1-11","journal-title":"Fitoterapia"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3109\/13880209.2014.991836","volume":"53","author":"Eskandani M.","year":"2015","unstructured":"Eskandani M.; Barar J.; Dolatabadi J.E.; Hamishehkar H.; Nazemiyeh H.; Formulation, characterization, and geno\/cytotoxicity studies of galbanic acid-loaded solid lipid nanoparticles. Pharm Biol 2015,53(10),1525-1538","journal-title":"Pharm Biol"},{"key":"ref=30","first-page":"237","volume":"9","author":"Jafari A.","year":"2019","unstructured":"Jafari A.; Teymouri M.; Ebrahimi Nik M.; Abbasi A.; Iranshahi M.; Hanafi-Bojd M.Y.; Jafari M.R.; Interactive anticancer effect of nanomicellar curcumin and galbanic acid combination therapy with some common chemotherapeutics in colon carcinoma cells. Avicenna J Phytomed 2019,9(3),237-247","journal-title":"Avicenna J Phytomed"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejphar.2019.01.028","volume":"847","author":"Kim Y.H.","year":"2019","unstructured":"Kim Y.H.; Shin E.A.; Jung J.H.; Park J.E.; Koo J.; Koo J.I.; Shim B.S.; Kim S.H.; Galbanic acid potentiates TRAIL induced apoptosis in resistant non-small cell lung cancer cells via inhibition of MDR1 and activation of caspases and DR5. Eur J Pharmacol 2019,847,91-96","journal-title":"Eur J Pharmacol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/ijc.25993","volume":"130","author":"Zhang Y.","year":"2012","unstructured":"Zhang Y.; Kim K.H.; Zhang W.; Guo Y.; Kim S.H.; L&#xFC; J.; Galbanic acid decreases androgen receptor abundance and signaling and induces G1 arrest in prostate cancer cells. Int J Cancer 2012,130(1),200-212","journal-title":"Int J Cancer"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/ptr.5320","volume":"29","author":"Oh B.S.","year":"2015","unstructured":"Oh B.S.; Shin E.A.; Jung J.H.; Jung D.B.; Kim B.; Shim B.S.; Yazdi M.C.; Iranshahi M.; Kim S.H.; Apoptotic effect of galbanic acid via activation of caspases and inhibition of Mcl-1 in H460 non-small lung carcinoma cells. Phytother Res 2015,29(6),844-849","journal-title":"Phytother Res"},{"key":"ref=34","first-page":"1643","volume":"24","author":"Kazemi M.","year":"2021","unstructured":"Kazemi M.; Kouhpeikar H.; Delbari Z.; Khodadadi F.; Gerayli S.; Iranshahi M.; Mosavat A.; Behnam Rassouli F.; Rafatpanah H.; Combination of auraptene and arsenic trioxide induces apoptosis and cellular accumulation in the subG1 phase in adult T-cell leukemia cells. Iran J Basic Med Sci 2021,24(12),1643-1649","journal-title":"Iran J Basic Med Sci"},{"key":"ref=35","first-page":"1934578X211072334","volume":"17","author":"Delbari Z.","year":"2022","unstructured":"Delbari Z.; Combination of umbelliprenin and arsenic trioxide acts as an effective modality against T-cell leukemia\/lymphoma cells. Nat. Prod. Commun. 2022,17(1),1934578X211072334"},{"key":"ref=36","first-page":"616","volume":"23","author":"Kouhpaikar H.","year":"2020","unstructured":"Kouhpaikar H.; Sadeghian M.H.; Rafatpanah H.; Kazemi M.; Iranshahi M.; Delbari Z.; Khodadadi F.; Ayatollahi H.; Rassouli F.B.; Synergy between parthenolide and arsenic trioxide in adult T-cell leukemia\/lymphoma cells in vitro. Iran J Basic Med Sci 2020,23(5),616-622","journal-title":"Iran J Basic Med Sci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1182\/blood.V91.7.2467","volume":"91","author":"Lau A.","year":"1998","unstructured":"Lau A.; Nightingale S.; Taylor G.P.; Gant T.W.; Cann A.J.; Enhanced MDR1 gene expression in human T-cell leukemia virus-I-infected patients offers new prospects for therapy. Blood 1998,91(7),2467-2474","journal-title":"Blood"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/sj.onc.1203450","volume":"19","author":"Ariumi Y.","year":"2000","unstructured":"Ariumi Y.; Kaida A.; Lin J.Y.; Hirota M.; Masui O.; Yamaoka S.; Taya Y.; Shimotohno K.; HTLV-1 tax oncoprotein represses the p53-mediated trans-activation function through coactivator CBP sequestration. Oncogene 2000,19(12),1491-1499","journal-title":"Oncogene"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1089\/08892220050193146","volume":"16","author":"Haller K.","year":"2000","unstructured":"Haller K.; Ruckes T.; Schmitt I.; Saul D.; Derow E.; Grassmann R.; Tax-dependent stimulation of G1 phase-specific cyclin-dependent kinases and increased expression of signal transduction genes characterize HTLV type 1-transformed T cells. AIDS Res Hum Retroviruses 2000,16(16),1683-1688","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref=40","first-page":"2360","volume":"93","author":"Mori N.","year":"1999","unstructured":"Mori N.; Fujii M.; Ikeda S.; Yamada Y.; Tomonaga M.; Ballard D.W.; Yamamoto N.; Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood 1999,93(7),2360-2368","journal-title":"Blood"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"5952","DOI":"10.1038\/sj.onc.1208969","volume":"24","author":"Sun S.C.","year":"2005","unstructured":"Sun S.C.; Yamaoka S.; Activation of NF-kappaB by HTLV-I and implications for cell transformation. Oncogene 2005,24(39),5952-5964","journal-title":"Oncogene"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1146\/annurev.immunol.19.1.475","volume":"19","author":"Yoshida M.","year":"2001","unstructured":"Yoshida M.; Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol 2001,19(1),475-496","journal-title":"Annu Rev Immunol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"5938","DOI":"10.1038\/sj.onc.1208973","volume":"24","author":"Kashanchi F.","year":"2005","unstructured":"Kashanchi F.; Brady J.N.; Transcriptional and post-transcriptional gene regulation of HTLV-1. Oncogene 2005,24(39),5938-5951","journal-title":"Oncogene"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nrc2111","volume":"7","author":"Matsuoka M.","year":"2007","unstructured":"Matsuoka M.; Jeang K-T.; Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007,7(4),270-280","journal-title":"Nat Rev Cancer"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1101\/gad.9.10.1149","volume":"9","author":"Sherr C.J.","year":"1995","unstructured":"Sherr C.J.; Roberts J.M.; Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995,9(10),1149-1163","journal-title":"Genes Dev"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1084\/jem.190.7.1025","volume":"190","author":"Djerbi M.","year":"1999","unstructured":"Djerbi M.; Screpanti V.; Catrina A.I.; Bogen B.; Biberfeld P.; Grandien A.; The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med 1999,190(7),1025-1032","journal-title":"J Exp Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1084\/jem.190.7.1033","volume":"190","author":"Medema J.P.","year":"1999","unstructured":"Medema J.P.; de Jong J.; van Hall T.; Melief C.J.; Offringa R.; Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 1999,190(7),1033-1038","journal-title":"J Exp Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1365-2443.2006.00927.x","volume":"11","author":"Okamoto K.","year":"2006","unstructured":"Okamoto K.; Fujisawa J.; Reth M.; Yonehara S.; Human T-cell leukemia virus type-I oncoprotein Tax inhibits Fas-mediated apoptosis by inducing cellular FLIP through activation of NF-kappaB. Genes Cells 2006,11(2),177-191","journal-title":"Genes Cells"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"603925","DOI":"10.1155\/2011\/603925","volume":"2011","author":"Ozaki T.","year":"2011","unstructured":"Ozaki T.; Nakagawara A.; p53: The attractive tumor suppressor in the cancer research field. J Biomed Biotechnol 2011,2011,603925","journal-title":"J Biomed Biotechnol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1182\/blood-2011-11-366062","volume":"119","author":"Xu-Monette Z.Y.","year":"2012","unstructured":"Xu-Monette Z.Y.; Medeiros L.J.; Li Y.; Orlowski R.Z.; Andreeff M.; Bueso-Ramos C.E.; Greiner T.C.; McDonnell T.J.; Young K.H.; Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood 2012,119(16),3668-3683","journal-title":"Blood"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/sj.onc.1204124","volume":"20","author":"Bartke T.","year":"2001","unstructured":"Bartke T.; Siegmund D.; Peters N.; Reichwein M.; Henkler F.; Scheurich P.; Wajant H.; p53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene 2001,20(5),571-580","journal-title":"Oncogene"}],"container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871520622666220722105802","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/206991\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871520622666220722105802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T10:01:05Z","timestamp":1680602465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/206991\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871520622666220722105802","relation":{},"ISSN":["1871-5206"],"issn-type":[{"value":"1871-5206","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-03-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"0002-06-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}